Skip to content
value.today

Radiance Therapeutics, Inc.

🇺🇸 Tucson, Arizona, USAHealth CareFounded 2018
Total raised
$19 M
3 rounds on record
Latest round
$9 M
Dec 2020
First round on record
Jul 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Radiance Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$9 MNo. 3$2 to $10 million

Radiance Therapeutics, Inc.: Raise no. 3, Dec 2020

Investors in this round

51 investors had bought by the notice of Jun 29, 2023: 51 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $11 M offered; $2 M still to sell
Smallest investment taken
$1,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$129,573
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • G. Todd John Silva · Executive Officer
  • Laurence John Marsteller · Executive Officer, Director
  • Ken John Abrahams · Director
  • Marc John Sandroff · Director
  • Peng John Khaw · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Wilmington Capital Securities, LLC (CRD 133839) · Garden City, New YorkSold in CA, FL, IL, and outside the US

Remarks in the notice

  • On the amounts: “Extension of time and increase offering amount for bridge note financing”

Signed by Laurence J. Marsteller, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Jun 29, 2023. Read the notice at the SEC.

debt, optionsSEC
Jan 2019$6 MNo. 2$2 to $10 million

Radiance Therapeutics, Inc.: Raise no. 2, Jan 2019

Investors in this round

60 investors had bought by the notice of Oct 26, 2020: 60 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Laurence John Marsteller · Executive Officer, Director
  • Harry Allan George · Director
  • Ken John Abrahams · Director
  • Marc John Sandroff · Director
  • Peng John Khaw · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Increase in total amount of offering.”

Signed by Laurence Marsteller, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 26, 2020. Read the notice at the SEC.

equitySEC
Jul 2018$4 MNo. 1$2 to $10 million

Radiance Therapeutics, Inc.: Raise no. 1, Jul 2018

Investors in this round

45 investors had bought by the notice of Jan 23, 2019: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Allan George · Executive Officer, Director
  • Laurence John Marsteller · Executive Officer, Director
  • Peng John Khaw · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Increase in total offering amount and amount sold.”

Signed by Laurence Marsteller, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 23, 2019. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Radiance Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2023

That is all the official record says: Radiance Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Radiance Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 60 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Radiance Therapeutics, Inc.
NameRoleNamed in
G. Todd John SilvaExecutive officerJun 2023
Laurence John MarstellerExecutive officerJun 2023
Harry Allan GeorgeExecutive officerJan 2019
Ken John AbrahamsDirectorJun 2023
Laurence John MarstellerDirectorJun 2023
Marc John SandroffDirectorJun 2023
Peng John KhawDirectorJun 2023
Harry Allan GeorgeDirectorDec 2020